Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.

O'Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Mc Nulty A, Marchal C, Kalous O, von Euw E, Hurvitz S, Mockbee C, Slamon DJ.

Mol Cancer Ther. 2018 May;17(5):897-907. doi: 10.1158/1535-7163.MCT-17-0290. Epub 2018 Feb 26.

2.

Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.

Fejzo MS, Anderson L, Chen HW, Guandique E, Kalous O, Conklin D, Slamon DJ.

Genes Chromosomes Cancer. 2017 Aug;56(8):589-597. doi: 10.1002/gcc.22459. Epub 2017 May 4.

PMID:
28316110
3.

In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.

Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ.

Breast Cancer Res Treat. 2015 Feb;149(3):669-80. doi: 10.1007/s10549-015-3282-x. Epub 2015 Feb 8.

PMID:
25663547
4.

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.

O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ.

Clin Cancer Res. 2014 Jul 1;20(13):3507-20. doi: 10.1158/1078-0432.CCR-13-2769. Epub 2014 May 30.

5.

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.

Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS.

Breast Cancer Res Treat. 2013 Oct;141(3):397-408. doi: 10.1007/s10549-013-2702-z. Epub 2013 Oct 5.

PMID:
24091768
6.

Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS.

Mol Cancer Ther. 2013 Apr;12(4):509-19. doi: 10.1158/1535-7163.MCT-12-0507. Epub 2013 Feb 8.

7.

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer.

Fejzo MS, Anderson L, von Euw EM, Kalous O, Avliyakulov NK, Haykinson MJ, Konecny GE, Finn RS, Slamon DJ.

Int J Mol Sci. 2013 Feb 1;14(2):3094-109. doi: 10.3390/ijms14023094.

8.

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.

Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.

Mol Cancer Ther. 2012 Sep;11(9):1978-87. doi: 10.1158/1535-7163.MCT-11-0730. Epub 2012 Jul 3.

9.

Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.

Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP.

Clin Cancer Res. 2011 Nov 15;17(22):7093-104. doi: 10.1158/1078-0432.CCR-11-0578. Epub 2011 Sep 20.

10.

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ.

Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.

11.

Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity.

Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP.

Clin Cancer Res. 2008 Jan 15;14(2):533-40. doi: 10.1158/1078-0432.CCR-06-2289.

12.

Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.

Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP.

Clin Cancer Res. 2007 May 15;13(10):3079-86.

13.

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.

Frgala T, Kalous O, Proffitt RT, Reynolds CP.

Mol Cancer Ther. 2007 Mar;6(3):886-97.

14.

DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.

Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP.

Methods Mol Med. 2005;110:139-53. Review.

PMID:
15901933
15.

[High-dose busulfan--monitoring plasma levels and dosage adjustments in adults].

Kalous O, Mayer J, Malásková L.

Cas Lek Cesk. 2001 Nov 22;140(23):724-8. Review. Czech.

PMID:
11787234
16.

[Who was Mr. McBean and what resulted from his death?].

Doubek M, Kalous O, Oborilová A.

Vnitr Lek. 2000 Oct;46(10):732-5. Czech.

PMID:
11344636

Supplemental Content

Loading ...
Support Center